Skip to main content

MS therapies: what is in the Pipeline

This webinar was presented at the first International Neuroimmunology Conference INIC 2024 1-2 March 2024 in Riyadh, Saudi Arabia. Professor Nicolas Grigoriadis talked about advancements in treating multiple sclerosis (MS) – from general treatments like Copaxone and interferons to more targeted therapies, such as monoclonal antibodies, which focus on controlling T and B cell activity. The current research indicates that microglial cells play a crucial role in ongoing neurodegeneration and disability progression, suggesting the need for treatments targeting these cells. New therapies in the pipeline, such as anti-CD20 monoclonal antibodies and BTK inhibitors, show promise in addressing both B cells in the brain and microglial activity to better manage MS progression.

BIOGRAPHY

Nikolaos Grigoriadis

Professor of Neurology at the Aristotle University of Thessaloniki

Dr Nikolaos Grigoriadis graduated from the Faculty of Medicine of the Aristotle University of Thessaloniki. He did his PhD thesis and residency in Neurology in the same institution. He has been specialized in clinical and experimental Neuroimmunology and CNS immunopathology in a number of research centers and institutions abroad.

He is now Professor of Neurology at the Aristotle University of Thessaloniki and Head of the of the B’ Dept of Neurology, AHEPA University Hospital, the MS Centre and the Laboratory of Experimental Neurology and Neuroimmunology (www.neuroimmunology.gr).

Professor Grigoriadis is member of various international scientific committees such as the European School of Neuroimmunology, ParadigMS, the subcommittee of ENS for Multiple Sclerosis, the ECTRIMS committee (until 2010), Co-founder and Secretary of the Hellenic Academy of Neuroimmunology (www.helani.gr). He is President of the Hellenic Neurological Society. He is Ad Hoc reviewer in more than 40 international scientific journals, co-ordinator in more than 40 multicenter clinical trials for MS and principal investigator in collaborative research projects for experimental cell therapies in CNS autoimmune demyelination.
His field of interests are: Neuroimmunology; Multiple sclerosis; experimental models of autoimmune diseases (EAE etc); neurodegeneration; immunomodulation; cell therapies. He has published more than 180 papers in peer reviewed journals. He has been awarded several times for his scientific work.


Media

Details

  • Directors

    ParadigMS
  • Author(s)

    Nicolaos Grigoriadis
  • Country

    Greece
  • Release Date

    June 27, 2024
  • Views

We value your opinion.

Selected Value: 1
Give a score from 1 (= not at all likely) to 10 (extremely likely)
Give your opinion on the quality of the material and send us your comments, questions or feedback. Where relevant, we'll liaise with the Expert and get back to you.
If you have submitted a question above, leave your email so we can get back to you.


FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.